Tolvaptan in autosomal dominant polycystic kidney disease: Three years' experience

Eiji Higashihara, Vicente E. Torres, Arlene B. Chapman, Jared J. Grantham, Kyongtae Bae, Terry J. Watnick, Shigeo Horie, Kikuo Nutahara, John Ouyang, Holly B. Krasa, Frank S. Czerwiec

Research output: Contribution to journalArticle

108 Scopus citations

Abstract

Summary Background and objectives: Autosomal dominant polycystic kidney disease (ADPKD), a frequent cause of end-stage renal disease, has no cure. V2-specific vasopressin receptor antagonists delay disease progression in animal models. Design, setting, participants, and measurements This is a prospectively designed analysis of annual total kidney volume (TKV) and thrice annual estimated GFR (eGFR) measurements, from two 3-year studies of tolvaptan in 63 ADPKD subjects randomly matched 1:2 to historical controls by gender, hypertension, age, and baseline TKV or eGFR. Prespecified end points were group differences in log-TKV (primary) and eGFR (secondary) slopes for month 36 completers, using linear mixed model (LMM) analysis. Sensitivity analyses of primary and secondary end points included LMM using all subject data and mixed model repeated measures (MMRM) of change from baseline at each year. Pearson correlation tested the association between log-TKV and eGFR changes. Results: Fifty-one subjects (81%) completed 3 years of tolvaptan therapy; all experienced adverse events (AEs), with AEs accounting for six of 12 withdrawals. Baseline TKV (controls 1422, tolvaptan 1635 ml) and eGFR (both 62 ml/min per 1.73 m 2) were similar. Control TKV increased 5.8% versus 1.7%/yr for tolvaptan (P < 0.001, estimated ratio of geometric mean 0.96 [95% confidence interval 0.95 to 0.97]). Corresponding annualized eGFR declined: -2.1 versus -0.71 ml/min per 1.73 m 2/yr (P = 0.01, LMM group difference 1.1 ml/min per 1.73 m2/yr [95% confidence interval 0.24 to 1.9]). Sensitivity analyses including withdrawn subjects were similar, whereas MMRM analyses were significant at each year for TKV and nonsignificant for eGFR. Increasing TKV correlated with decreasing eGFR (r = -0.21, P < 0.01). Conclusion ADPKD cyst growth progresses more slowly with tolvaptan than in historical controls, but AEs are common.

Original languageEnglish (US)
Pages (from-to)2499-2507
Number of pages9
JournalClinical Journal of the American Society of Nephrology
Volume6
Issue number10
DOIs
StatePublished - Oct 1 2011

    Fingerprint

ASJC Scopus subject areas

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation

Cite this

Higashihara, E., Torres, V. E., Chapman, A. B., Grantham, J. J., Bae, K., Watnick, T. J., Horie, S., Nutahara, K., Ouyang, J., Krasa, H. B., & Czerwiec, F. S. (2011). Tolvaptan in autosomal dominant polycystic kidney disease: Three years' experience. Clinical Journal of the American Society of Nephrology, 6(10), 2499-2507. https://doi.org/10.2215/CJN.03530411